Anaphylaxis Archives - MPR

Anaphylaxis

FDA Committee Votes on Palforzia for Peanut Allergy

The FDA’s Allergenic Products Advisory Committee voted in favor of the approval of Palforzia (AR101; Aimmune Therapeutics) as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients 4 through 17 years old with a confirmed diagnosis of peanut allergy.